SCHEMBL3679863

SCHEMBL3679863

O=C(O)C1=C(C(=O)O)COC1

nearest known ligand 0.37

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 1/20 0.37
DHODH Q02127 4/20 0.32
PYGM P11217 1/20 0.31
NR4A2 P43354 1/20 0.31
CYP1A2 P05177 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31451266 0.75
SCHEMBL15902275 0.73
SCHEMBL28247944 0.70 FABP4 (0.33)
SCHEMBL252263 0.69 DHODH (0.45) HCAR2DHODH
SCHEMBL168735 0.67 PYGM (0.35) DHODHPYGM
SCHEMBL1428318 0.67 PYGM (0.35) DHODHPYGM
SCHEMBL11430568 0.67 FFAR3 (0.36) PYGMCYP1A2
SCHEMBL1286030 0.67 PYGM (0.35) DHODHPYGM
SCHEMBL2296442 0.67
SCHEMBL17024326 0.62 DHODH (0.41) HCAR2DHODH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250066290-A1 DHODH INHIBITORS CONTAINING A CARBOXYLIC ACID BIOISOSTERE IMMUNIC AG (DE) 2025-02-27 US disclosed
EP-4452929-A1 DHODH INHIBITORS CONTAINING A CARBOXYLIC ACID BIOISOSTERE Immunic AG (DE) 2024-10-30 EP disclosed
CN-118382610-A DHODH inhibitors containing carboxylic acid bioisosteres 埃慕尼克股份公司 2024-07-23 CN disclosed
CN-110038575-B Method for preparing specific selective hydrogenation catalysts by kneading and impregnation IFP 新能源公司 2023-10-10 CN disclosed
WO-2023118576-A1 DHODH INHIBITORS CONTAINING A CARBOXYLIC ACID BIOISOSTERE IMMUNIC AG (DE) 2023-06-29 WO disclosed
WO-2023118576-A1 DHODH INHIBITORS CONTAINING A CARBOXYLIC ACID BIOISOSTERE IMMUNIC AG (DE) 2023-06-29 WO disclosed
EP-3559165-B1 SELECTIVE HYDROGENATION PROCESS WITH A NICKEL BASED CATALYST PREPARED BY AN ADDITIVE HAVING A CARBOXYLIC ACID FUNCTION IFP ENERGIES NOW (FR) 2022-09-14 EP disclosed
US-11439994-B2 Method for the hydrogenation of aromatics using a nickel-based catalyst IFP Energies Nouvelles (FR) 2022-09-13 US disclosed
US-10927310-B2 Selective hydrogenation method using a nickel-based catalyst produced using an additive comprising a carboxylic acid function IFP Energies Nouvelles (FR) 2021-02-23 US disclosed
US-20210031179-A1 METHOD FOR THE HYDROGENATION OF AROMATICS USING A NICKEL-BASED CATALYST IFP Energies Nouvelles (FR) 2021-02-04 US disclosed
EP-2093214-A1 Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents 4SC AG (DE) 2009-08-26 EP disclosed
CN-100462352-C Novel compounds useful as anti-inflammatory, immunomodulatory and antiproliferative agents 4SC AG (DE) 2009-02-18 CN disclosed
US-7423057-B2 Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents 4SC AG (DE) 2008-09-09 US disclosed
US-7176241-B2 Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents 4SC AG (DE) 2007-02-13 US disclosed
US-20060199856-A1 Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents 4 SC AG (DE) 2006-09-07 US disclosed
CN-1525954-A Novel compounds useful as anti-inflammatory, immunomodulatory and antiproliferative agents 4SC�ɷݹ�˾ 2004-09-01 CN disclosed
EP-1392642-A2 NOVEL COMPOUNDS AS ANTI-INFLAMMATORY, IMMUNOMODULATORY AND ANTI-PROLIFERATORY AGENTS 4SC AG (DE) 2004-03-03 EP disclosed
WO-2003006425-A9 NOVEL COMPOUNDS AS ANTI-INFLAMMATORY, IMMUNOMODULATORY AND ANTI-PROLIFERATORY AGENTS 4SC AG (DE) 2004-02-26 WO disclosed
US-20030203951-A1 Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents 4SC AG (DE) 2003-10-30 US disclosed
WO-2003006425-A2 NOVEL COMPOUNDS AS ANTI-INFLAMMATORY, IMMUNOMODULATORY AND ANTI-PROLIFERATORY AGENTS 4SC AG (DE) 2003-01-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030203951-A1 Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents DHODH, DLD, GCDH HCAR2 150/4885DHODH 1/4885PYGM 3339/4885
US-20060199856-A1 Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents DHODH, DLD, HADHA HCAR2 158/4885DHODH 1/4885PYGM 2989/4885
US-20250066290-A1 DHODH INHIBITORS CONTAINING A CARBOXYLIC ACID BIOISOSTERE DHODH, DBH, DOHH HCAR2 79/4885DHODH 1/4885PYGM 2594/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.